Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00093847 · ClinicalTrials.gov registry record · Phase 2
Optimizing the Effectiveness of Selective Serotonin Reuptake Inhibitors (SSRIs) in Treatment-Resistant Depression
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 73
- Enrollment target
NCT00093847: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT00093847 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 73 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00093847, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 73 participants
- Enrollment target
Study Summary
This study will determine the effectiveness of adding S-adenosyl methionine to antidepressant drug treatment in reducing depressive symptoms in depressed people who have not responded to antidepressants alone.
Interventions
- DRUG Placebo
- DRUG S-adenosyl methione (SAMe)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2004-05 |
| Est. Completion | 2009-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00093847
The ClinicalTrials.gov registry entry for NCT00093847 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00093847 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00093847 about?
NCT00093847 is a clinical study titled "Optimizing the Effectiveness of Selective Serotonin Reuptake Inhibitors (SSRIs) in Treatment-Resistant Depression". This study will determine the effectiveness of adding S-adenosyl methionine to antidepressant drug treatment in reducing depressive symptoms in depressed people who have not responded to antidepressants alone.
What is the current status of trial NCT00093847?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 73 participants. The study started on 2004-05. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00093847?
The interventions under investigation include: Placebo (DRUG), S-adenosyl methione (SAMe) (DRUG).
Who is sponsoring clinical trial NCT00093847?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.